Catalog Products » Growth Factors » PEDF, Human
Manual
Manual
COAs

PEDF, Human

PEDF is a noninhibitory serpin with neurotrophic, anti-angiogenic, and anti-tumorigenic properties. It is a 50 kDa glycoprotein produced and secreted in many tissues throughout the body. A major component of the anti-angiogenic action of PEDF is the induction of apoptosis in proliferating endothelial cells. In addition, PEDF is able to inhibit the activity of angiogenic factors such as VEGF and FGF-2. The neuroprotective effects of PEDF are achieved through suppression of neuronal apoptosis induced by peroxide, glutamate, or other neurotoxins. The recent identification of a lipase-linked cell membrane receptor for PEDF (PEDF-R) that binds to PEDF with high affinity should facilitate further elucidation of the underlying mechanisms of this pluripotent serpin. To date, PEDF-R is the only signaling receptor known to be used by a serpin family member. The unique range of PEDF activities implicate it as a potential therapeutic agent for the treatment of vasculature related neurodegenerative diseases such as age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). PEDF also has the potential to be useful in the treatment of various angiogenesis-related diseases including a number of cancers.
$180.00
Z02722-20

Ask us a question
Product Introduction
Species Human
Protein Construction
PEDF (Gln20-Pro418)
Accession # P36955
Purity > 97% as analyzed by SDS-PAGE
> 97% as analyzed by HPLC
Endotoxin Level < 1 EU/μg of protein by LAL method
Biological Activity Fully biologically active when compared to standard. The ED50 as determined by its ability to enhance the adhesion of human Saos2 cells to bovine Collagen I coated plate is less than 2.0 ng/ml, corresponding to a specific activity of > 5.0 × 105 IU/mg.
Expression System E. coli
Theoretical Molecular Weight 44.4 kDa
Formulation Lyophilized from a 0.2 μm filtered solution in 20 mM PB, pH 7.4, 150 mM NaCl.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml.
Storage & Stability Upon receiving, this product remains stable for 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for 1 week at 4°C or for 3 months at -20°C. Avoid repeated freeze-thaw cycles.
Back

PEDF, Human

»

PEDF, Human

»

<
>

Background
Target Background PEDF is a noninhibitory serpin with neurotrophic, anti-angiogenic, and anti-tumorigenic properties. It is a 50 kDa glycoprotein produced and secreted in many tissues throughout the body. A major component of the anti-angiogenic action of PEDF is the induction of apoptosis in proliferating endothelial cells. In addition, PEDF is able to inhibit the activity of angiogenic factors such as VEGF and FGF-2. The neuroprotective effects of PEDF are achieved through suppression of neuronal apoptosis induced by peroxide, glutamate, or other neurotoxins. The recent identification of a lipase-linked cell membrane receptor for PEDF (PEDF-R) that binds to PEDF with high affinity should facilitate further elucidation of the underlying mechanisms of this pluripotent serpin. To date, PEDF-R is the only signaling receptor known to be used by a serpin family member. The unique range of PEDF activities implicate it as a potential therapeutic agent for the treatment of vasculature related neurodegenerative diseases such as age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). PEDF also has the potential to be useful in the treatment of various angiogenesis-related diseases including a number of cancers.
Synonyms SERPINF1; EPC-1; OI12; OI6; PEDF; PIG35; serpin family F member 1; Pigment epithelium-derived factor
Back

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.